PMID- 29783126
OWN - NLM
STAT- MEDLINE
DCOM- 20180801
LR  - 20220410
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 68
DP  - 2018 Jul
TI  - Systemic therapy for intermediate and advanced hepatocellular carcinoma: 
      Sorafenib and beyond.
PG  - 16-24
LID - S0305-7372(18)30075-6 [pii]
LID - 10.1016/j.ctrv.2018.05.006 [doi]
AB  - The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with 
      sorafenib demonstrating survival benefit in the first-line setting and becoming 
      the first systemic therapy to be approved for HCC. More recently, regorafenib and 
      nivolumab have received approval in the second-line setting after sorafenib, with 
      further positive phase 3 studies emerging in the first line (lenvatinib 
      non-inferior to sorafenib) and second line versus placebo (cabozantinib and 
      ramucirumab). A key recommendation in the management of patients receiving 
      sorafenib is to promote close communication between the patient and the physician 
      so that adverse events (AEs) are detected early and severe AEs can be prevented. 
      Sorafenib-related AEs have been identified as clinical biomarkers for sorafenib 
      efficacy. Healthcare professionals have become more efficient in managing AEs, 
      identifying patients who are likely to benefit from treatment, and assessing 
      response to treatment, resulting in a trend towards increased overall survival in 
      the sorafenib arms of clinical studies. The rapidly changing treatment landscape 
      due to the emergence of new treatment options (sorafenib and lenvatinib equally 
      effective in first line; regorafenib, cabozantinib, and ramucirumab showing OS 
      benefit in second line with nivolumab approved by the FDA based on response rate) 
      underscores the importance of re-assessing the role of the first approved 
      systemic agent in HCC, sorafenib.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Raoul, Jean-Luc
AU  - Raoul JL
AD  - Digestive Oncology, Institut de Cancerologie de l'Ouest, Boulevard Professeur 
      Jacques Monod, 44805 Nantes-Saint Herblain, France. Electronic address: 
      jean-luc.raoul@ico.unicancer.fr.
FAU - Kudo, Masatoshi
AU  - Kudo M
AD  - Department of Gastroenterology and Hepatology, Kindai University Faculty of 
      Medicine, 377-2 Ohno-Higashi, 589-8511 Osaka, Japan. Electronic address: 
      m-kudo@med.kindai.ac.jp.
FAU - Finn, Richard S
AU  - Finn RS
AD  - Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Le 
      Conte Ave, 90095 Los Angeles, CA, USA. Electronic address: RFinn@mednet.ucla.edu.
FAU - Edeline, Julien
AU  - Edeline J
AD  - Medical Oncology, Centre Eugene Marquis, Avenue de la Bataille 
      Flandres-Dunkerque, 35000 Rennes, France. Electronic address: 
      j.edeline@rennes.unicancer.fr.
FAU - Reig, Maria
AU  - Reig M
AD  - BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, 
      CIBEREHD, Villarroel 170, 08036 Barcelona, Spain. Electronic address: 
      MREIG1@clinic.cat.
FAU - Galle, Peter R
AU  - Galle PR
AD  - I. Medical Department, Mainz University Medical Center, Langenbeckstrasse 1, 55131 
      Mainz, Germany. Electronic address: Peter.Galle@unimedizin-mainz.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180526
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/adverse effects
MH  - Carcinoma, Hepatocellular/*drug therapy
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Liver Neoplasms/*drug therapy
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & derivatives
MH  - Phenylurea Compounds/*administration & dosage/adverse effects
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Sorafenib
OTO - NOTNLM
OT  - Advanced HCC
OT  - Regorafenib
OT  - Sorafenib
OT  - Systemic therapy
EDAT- 2018/05/22 06:00
MHDA- 2018/08/02 06:00
CRDT- 2018/05/22 06:00
PHST- 2018/01/23 00:00 [received]
PHST- 2018/05/11 00:00 [revised]
PHST- 2018/05/12 00:00 [accepted]
PHST- 2018/05/22 06:00 [pubmed]
PHST- 2018/08/02 06:00 [medline]
PHST- 2018/05/22 06:00 [entrez]
AID - S0305-7372(18)30075-6 [pii]
AID - 10.1016/j.ctrv.2018.05.006 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 
      May 26.